专利检索 ap:("ISIS PHARMACEUTICALS INC") AND inv:"NOZAKI CHIKATERU" 第 1 页

1.

发明公开
COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS C VIRUS-ASSOCIATED DISEASES 有权
标题翻译：组合物和方法用于治疗丙型肝炎病毒相关疾病的治疗

公开(公告)号：EP1035870A4

公开(公告)日：2003-01-02

申请号：EP98960818

申请日：1998-12-08

申请人： ISIS PHARMACEUTICALS INC

发明人： ANDERSON KEVIN P , HANECAK RONNIE C , NOZAKI CHIKATERU

IPC分类号： C12N15/09 , A61K31/711 , A61K38/00 , A61K38/21 , A61K48/00 , A61P1/16 , A61P31/20 , C07H21/04 , C07K14/18 , C12N15/113 , C12Q1/70 , C12Q1/68

CPC分类号： C12N15/1131 , A61K38/00 , C07K14/005 , C12N2310/315 , C12N2310/318 , C12N2310/3181 , C12N2310/321 , C12N2310/322 , C12N2310/3233 , C12N2310/33 , C12N2310/334 , C12N2310/341 , C12N2310/346 , C12N2770/24222 , C12Q1/707 , C12N2310/3525 , C12N2310/3527 , C12N2310/3521

摘要： Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.